Integrated Wealth Concepts LLC Grows Stake in Abbott Laboratories $ABT

Integrated Wealth Concepts LLC increased its stake in Abbott Laboratories (NYSE:ABT) by 40.2% during the second quarter, HoldingsChannel reports. The firm owned 54,074 shares of the healthcare product maker’s stock after acquiring an additional 15,510 shares during the period. Integrated Wealth Concepts LLC’s holdings in Abbott Laboratories were worth $4,907,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently made changes to their positions in the company. Community Bank N.A. boosted its position in Abbott Laboratories by 3.9% during the second quarter. Community Bank N.A. now owns 41,593 shares of the healthcare product maker’s stock worth $3,774,000 after purchasing an additional 1,555 shares during the period. IFP Advisors Inc boosted its holdings in Abbott Laboratories by 307.1% in the 2nd quarter. IFP Advisors Inc now owns 234,173 shares of the healthcare product maker’s stock worth $21,249,000 after buying an additional 176,649 shares during the period. Ramsay Stattman Vela & Price Inc. grew its stake in Abbott Laboratories by 2.5% in the 2nd quarter. Ramsay Stattman Vela & Price Inc. now owns 104,942 shares of the healthcare product maker’s stock valued at $9,522,000 after buying an additional 2,573 shares in the last quarter. CORDA Investment Management LLC. raised its holdings in Abbott Laboratories by 1.5% during the 2nd quarter. CORDA Investment Management LLC. now owns 15,403 shares of the healthcare product maker’s stock valued at $1,398,000 after acquiring an additional 230 shares during the period. Finally, Allworth Financial LP lifted its position in shares of Abbott Laboratories by 1.2% during the second quarter. Allworth Financial LP now owns 255,765 shares of the healthcare product maker’s stock worth $23,208,000 after acquiring an additional 2,952 shares in the last quarter. 75.18% of the stock is currently owned by institutional investors.

Abbott Laboratories Trading Down 1.2%

Abbott Laboratories stock opened at $102.08 on Friday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.97 and a current ratio of 1.38. Abbott Laboratories has a fifty-two week low of $81.97 and a fifty-two week high of $137.49. The stock has a market cap of $176.63 billion, a P/E ratio of 33.03, a PEG ratio of 1.89 and a beta of 0.59. The firm’s fifty day moving average price is $105.60 and its 200-day moving average price is $99.85.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The company had revenue of $12.59 billion during the quarter, compared to analyst estimates of $12.52 billion. During the same quarter last year, the company earned $1.26 earnings per share. The firm’s quarterly revenue was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Equities research analysts forecast that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have recently commented on ABT. Citigroup raised their price target on Abbott Laboratories from $108.00 to $112.00 and gave the stock a “buy” rating in a report on Friday, July 17th. The Goldman Sachs Group dropped their price objective on Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating on the stock in a report on Wednesday, May 27th. Weiss Ratings upgraded Abbott Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, August 6th. Wells Fargo & Company lifted their target price on Abbott Laboratories from $109.00 to $112.00 and gave the company an “overweight” rating in a report on Friday, July 17th. Finally, Wolfe Research upgraded Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 price target on the stock in a research report on Thursday, August 13th. Three research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $119.50.

Abbott Laboratories Company Profile

Abbott Laboratories (NYSE: ABT) is a global healthcare company that develops, manufactures and sells medical products and technologies. Its operations span four principal areas: medical devices, diagnostics, established pharmaceutical products and nutrition. Abbott serves healthcare providers, institutions and consumers in markets around the world.

The company’s medical device portfolio includes products for cardiovascular care, diabetes management and other specialties. Its diagnostics business provides laboratory systems, tests and point-of-care solutions, while its nutrition products include infant, child and adult nutritional offerings sold under brands such as Similac, Ensure and Pedialyte.